Cancer Immunotherapy Clinical Trials with Dr. Ezra Cohen

How to find and enroll in a cancer immunotherapy clinical trial: Dr. Ezra Cohen shares what to expect and addresses common misconceptions. #CRIsummit #immunotherapy #ClinicalTrials

In this video, Dr. Ezra Cohen busts these clinical trial myths:
- Myth: "I might only get placebo or a sugar pill instead of treatment."
- Myth: "Clinical trials are only for people who have run out of treatment options."
- Myth: "I need to travel to a large hospital or cancer center to participate in a clinical trial."
- Myth: "My health insurance doesn't cover the cost of care in a clinical trial."
- Myth: "Signing a consent form locks me into staying in a clinical trial."
- Myth: "I will be made to feel like a guinea pig experiment."
- Myth: "Clinical trials aren't safe."

Dr. Ezra Cohen answers viewer questions about clinical trials:
- "Does a physician always have to make a referral for you to join a clinical trial?"
- "What is the length of time you are generally on a clinical trial? Can you decide to stay on a trial longer if the treatment is working?"
- "Can you decide to stay on a trial longer if the treatment is right working?"
- "Can immunotherapy with other types of cancer treatment like chemotherapy and radiation?"
- “Will tumor genome testing hurt my chance of getting into an immunotherapy clinical trial?”
- "At what point in my treatment should I start looking for a clinical trial?"
- "How is COVID-19 impacting clinical research? Is it still safe to enroll in a clinical trial?"
- "What is the role of immunotherapy for patients with rare cancers?"
- "If I were to enroll in a clinical trial, would I lose my current oncologist?"

Dr. Ezra Cohen is chief of the Division of Hematology‐Oncology, and co‐director of the San Diego Center for Precision Immunotherapy. A physician‐scientist, Dr. Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics. He has made major contributions to targeted and immunotherapy. His research has received peer‐reviewed funding in the study of epidermal growth factor receptor inhibitors, cell therapy, and immunotherapy in head and neck cancer. He has made major contributions to the understanding of critical signaling pathways, integration of novel agents into standard of care, and definition of mechanisms to overcome resistance to drug therapy. He has also recently co‐developed a personalized neoantigen vaccine using unique cancer mutations to boost an anti‐tumor immune response.

Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.

[rhanna]

Nice review of clinical trials. Do you have 2 or 3 cancer immunotherapy clinical trials that you feel are very promising and if so what are they and brief thoughts on them. Thanks.